Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2005 1
2006 1
2007 3
2008 2
2009 8
2010 4
2011 8
2012 7
2013 11
2014 13
2015 8
2016 5
2017 8
2018 7
2019 5
2020 4
2021 10
2022 14
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Results by year

Filters applied: . Clear all
Page 1
Cervical cancer screening at crossroads.
Lynge E, Rygaard C, Baillet MV, Dugué PA, Sander BB, Bonde J, Rebolj M. Lynge E, et al. Among authors: rebolj m. APMIS. 2014 Aug;122(8):667-73. doi: 10.1111/apm.12279. APMIS. 2014. PMID: 25046198 Review.
Immunosuppression and risk of cervical cancer.
Dugué PA, Rebolj M, Garred P, Lynge E. Dugué PA, et al. Among authors: rebolj m. Expert Rev Anticancer Ther. 2013 Jan;13(1):29-42. doi: 10.1586/era.12.159. Expert Rev Anticancer Ther. 2013. PMID: 23259425 Review.
Cervical screening during the COVID-19 pandemic: optimising recovery strategies.
Castanon A, Rebolj M, Burger EA, de Kok IMCM, Smith MA, Hanley SJB, Carozzi FM, Peacock S, O'Mahony JF. Castanon A, et al. Among authors: rebolj m. Lancet Public Health. 2021 Jul;6(7):e522-e527. doi: 10.1016/S2468-2667(21)00078-5. Epub 2021 Apr 30. Lancet Public Health. 2021. PMID: 33939965 Free PMC article. Review.
Health impacts of COVID-19 disruptions to primary cervical screening by time since last screen: A model-based analysis for current and future disruptions.
Burger EA, de Kok IMCM, O'Mahony JF, Rebolj M, Jansen EEL, de Bondt DD, Killen J, Hanley SJ, Castanon A, Kim JJ, Canfell K, Smith MA, Regan MC. Burger EA, et al. Among authors: rebolj m. medRxiv [Preprint]. 2022 Jul 25:2022.07.25.22278011. doi: 10.1101/2022.07.25.22278011. medRxiv. 2022. PMID: 35923317 Free PMC article. Updated. Preprint.
HPV mRNA testing in cervical cancer screening.
Rossi PG, Rebolj M. Rossi PG, et al. Among authors: rebolj m. Lancet Oncol. 2022 Oct;23(10):e436. doi: 10.1016/S1470-2045(22)00486-7. Lancet Oncol. 2022. PMID: 36174617 No abstract available.
Not all HPV nucleic acid tests are equal: only those calibrated to detect high grade lesions matter for cervical screening: Response to 'Concordant testing results between various human papillomavirus assays in primary cervical cancer screening: systematic review' by de Thurah, Bonde, Uyen, Lam and Rebolj. Published 27 May, 2017.
de Thurah L, Bonde J, Lam JUH, Rebolj M. de Thurah L, et al. Among authors: rebolj m. Clin Microbiol Infect. 2018 Apr;24(4):438-439. doi: 10.1016/j.cmi.2017.12.001. Epub 2017 Dec 8. Clin Microbiol Infect. 2018. PMID: 29229428 Free article. No abstract available.
COVID-19 disruption to cervical cancer screening in England.
Castanon A, Rebolj M, Pesola F, Pearmain P, Stubbs R. Castanon A, et al. Among authors: rebolj m. J Med Screen. 2022 Sep;29(3):203-208. doi: 10.1177/09691413221090892. Epub 2022 Apr 4. J Med Screen. 2022. PMID: 35369792 Free PMC article.
104 results